Regeneron manufactures the intermediate at its Rensselaer, New York facility under an FDA-approved supplement to Merck's Establishment License Application.
What does ELA stand for?
ELA stands for Establishment License Application
This definition appears somewhat frequently
See other definitions of ELA
We have 169 other meanings of ELA in our Acronym Attic
- English Literary Association
- Enterprise License Agreement
- Enterprise Licensing Agreement
- Environmental Leadership Award (various organizations)
- Epanastatikos Laikos Agonas (Greek: Revolutionary Popular Struggle)
- Equilibrium Line Altitude
- Equipment Leasing Association of America
- Equipment Loan Agreement
- Esclerosis Lateral Amiotrópica (Spanish: Amyotrophic Lateral Sclerosis)
- Essential Learning Area (education)
- Estado Libre Asociado
- Études de Linguistique Appliquée (French: Applied Linguistics Studies)
- European Association for Education Law and Policy
- European Leukodystrophies Association
- European Lift Association (Belgium)
- European Light Aircraft (European Aviation Safety Agency)
- European Logistics Association
- Excellence in Leadership Award (various locations)
- Excess Loss Account (business taxation)
- Exchange Log Analyzer (software)
Samples in periodicals archive:
Additionally, King received a recent supplemental approval by the FDA to its Establishment License Application for the expansion of its Fluogen(R) production facility.
A complete review letter has been received for the THYMOGLOBULIN PLA, and FDA action on THYMOGLOBULIN's Establishment License Application (ELA) is expected soon.
A Product License and Establishment License Application for Verluma, a small cell lung cancer imaging agent developed by NeoRx, is in late stage review at the Food and Drug Administration.
A supplement to an approved Establishment License Application (ELA) to provide for the manufacturing process and facility for THYMOGLOBULIN was submitted and accepted for filing by the FDA in August 1996.
A Product License and Establishment License Application for Verluma(TM), a small cell lung cancer imaging agent developed by NeoRx, is in large stage review at the Food and Drug Administration.
19, 1996--SangStat, The Transplant Company(TM) (Nasdaq: SANG) and the IMTIX Division of Pasteur Merieux Connaught (Rhone-Poulenc group) today announced the filing of a supplement to an approved Establishment License Application (ELA) with the FDA for approval of the Pasteur Merieux manufacturing process and facility for THYMOGLOBULIN.
A Product License and Establishment License Application for the Company's first product, OncoTrac(R), is in late stage review at the Food and Drug Administration.